Microcrystalline cellulose
Osmoprep, Phosphates (microcrystalline cellulose) is an unknown pharmaceutical. Microcrystalline cellulose was first approved as Sodium phosphates in plastic container on 1983-05-10.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Osmoprep, Phosphates (generic drugs available since 2011-12-30, discontinued: Visicol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sodium phosphate
+
dibasic
+
anhydrous
+
Sodium phosphate
+
monobasic
+
monohydrate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
OSMOPREP | Salix Pharmaceuticals | N-021892 RX | 2006-03-16 | 1 products, RLD, RS |
Show 1 discontinued
Sodium phosphate
+
dibasic
+
heptahydrate
+
Sodium phosphate
+
monobasic
+
anhydrous
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SODIUM PHOSPHATES IN PLASTIC CONTAINER | Hospira | N-018892 RX | 1983-05-10 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
osmoprep | New Drug Application | 2019-03-04 |
potassium phosphates | unapproved drug other | 2022-07-12 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Sodium Phosphate, Dibasic, Anhydrous / Sodium Phosphate, Monobasic, Monohydrate, Osmoprep, Salix Pharms | |||
7687075 | 2028-06-22 | DS, DP |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB02: Hydrogen peroxide
D: Dermatologicals
— D08: Antiseptics and disinfectants
— D08A: Antiseptics and disinfectants
— D08AX: Other antiseptics and disinfectants in atc
— D08AX01: Hydrogen peroxide
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX25: Hydrogen peroxide
S: Sensory organ drugs
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA06: Hydrogen peroxide
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Surgical wound infection | D013530 | — | 2 | — | 6 | — | 8 | ||
Infections | D007239 | EFO_0000544 | — | — | — | 4 | 3 | 7 | |
Wound infection | D014946 | — | 1 | 1 | 1 | 1 | 3 | ||
Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | 1 | 1 | 2 |
Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 1 | 1 | 2 |
Post-lyme disease syndrome | D000077342 | — | — | — | 1 | — | 1 | ||
Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 1 | — | 1 |
Wounds and injuries | D014947 | T14.8 | — | — | — | 1 | — | 1 | |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
Streptococcal infections | D013290 | EFO_1001476 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Endophthalmitis | D009877 | 1 | 1 | — | — | 2 | 3 | ||
Antibiotic prophylaxis | D019072 | — | 2 | — | — | — | 2 | ||
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
Sinusitis | D012852 | EFO_0007486 | J32 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Communicable diseases | D003141 | — | — | — | — | 2 | 2 | ||
Erythema chronicum migrans | D015787 | A26.0 | — | — | — | — | 1 | 1 | |
Chemical and drug induced liver injury | D056486 | — | — | — | — | 1 | 1 | ||
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 1 | 1 |
Critical illness | D016638 | — | — | — | — | 1 | 1 | ||
Sepsis | D018805 | A41.9 | — | — | — | — | 1 | 1 | |
Septic shock | D012772 | A48.3 | — | — | — | — | 1 | 1 | |
Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | 1 | 1 | |
Pregnancy complications | D011248 | — | — | — | — | 1 | 1 | ||
Cataract | D002386 | EFO_0001059 | H26.9 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MICROCRYSTALLINE CELLULOSE |
INN | — |
Description | Lacrisert (microcrystalline cellulose) is an insert placed in the eye to treat moderate to severe dry eyes. It also can be used to treat the following eye conditions: exposure keratitis, decreased corneal sensitivity and recurrent corneal erosions. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
PDB | — |
CAS-ID | 12385-13-6 |
RxCUI | — |
ChEMBL ID | CHEMBL4297557 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 93,974 documents
View more details
Safety
Black-box Warning
Black-box warning for: Osmoprep
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
8,143 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more